FIRST-IN-CLASS SUPERIOR MAST CELL THERAPEUTICS
First-in-Class Superior Mast Cell Therapeutics targeting mast cells in major diseases areas with high need, across immunology, dermatology, respiratory, gastrointestinal and chronic inflammatory disorders.
Novel discovered scientific platform enables transformative treatments with superior efficacy and a strong safety profile.
Built from Survival.
Driven by Science.
Focused on Patients.
About us
MC Sciences is driven by a world-class team of leading drug development, science, medical and execution capabilities, and guided by board chairman Dr. Mikael Dolsten, former worldwide CSO of Pfizer.
Founded by Prof. Gerhard J. Molderings and the CEO Wolfgang Taumann, MC Sciences continues to be on track as emerging biotech company extensively expanding our leadership and drug development capabilities to advance our promising novel mast therapeutics to clinics.
MC Sciences is headquartered in Germany, with operations in Naples, Florida, and backed by ROC Venture Group.
Science
The company’s scientific platform is built on the novel discovery of a unique mast cell receptor that controls the entire mast cell activity unlocking the potential for transformative treatments with superior efficacy and a strong safety profile.
Drug Development
Our scientific breakthrough enables the development of both small- and large-molecule therapeutics tailored to address specific unmet needs of several major disease areas in dermatology, respiratory, gastrointestinal conditions, fibrotic diseases, chronic inflammation disorders and neuroinflammation.
Disease Areas
The therapeutic focus of MC is on major diseases such as chronic urticaria, systemic mastocytosis, COPD, asthma, food allergy, pulmonary and liver fibrosis, and in addition often “hidden” chronic inflammation disorders such as MCAS, fibromyalgia, IBS, long covid and chronic lyme.
What Makes MC Sciences Different
First-in-class based on novel discovered biology.
Expected superior profile with unique complete silencing selectively only of those mast cells that contribute to the disease resulting in expected superior therapeutic efficacy and strong safety.
In-human validated pharmacology and corresponding human ex-vivo validation with expected high probability for clinical success.
Built from Survival.
Driven by Science.
Focused on Patients.
Wolfgang Taumann, CEO and Co-Founder of MC Sciences:
“I took on the challenge to create MC Sciences as an opportunity to truly make a difference in this world. MC Sciences continues to be on track as emerging biotech company to advance our promising novel mast therapeutics to clinics.”
